Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 151 clinical trials
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC neoSCORE

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

non-small cell lung cancer
myocardial infarction
sintilimab
mental illness
small cell lung cancer
  • 0 views
  • 19 Feb, 2024
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers.

cancer treatment
hair thinning
ovarian cancer
cancer therapy
solid neoplasm
  • 0 views
  • 19 Feb, 2024
Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients

The study is devoted to the comparative analysis of the data received in patients with COVID-19 lung pathology using the method of probe-based confocal laser endomicroscopy of distal airways and two reference methods: high resolution computed tomography and morphology (in some patients).

lung disease
covid-19
critical illness
critically ill
pneumonia
  • 0 views
  • 19 Feb, 2024
A081801 / RLUN20119 / ALCHEMIST-IO (ACCIO) / Yuhchyau Chen  

Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB IIIA or IIIB non-small cell lung cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver and brain.

congestive heart failure
myocardial infarction
dementia
cerebrovascular disease
non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Carotid Doppler and EEOT for Fluid Responsiveness Prediction

In clinical practice, functional hemodynamic tests (FHT) consisting of maneuvers that affect cardiac function and/or heart-lung interaction, have been introduced in order to identify fluid responders and non-responders without fluid challenge administration.

stroke
  • 0 views
  • 19 Feb, 2024
Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection

An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection

fever
covid-19
cough
dyspnea
pneumonia
  • 0 views
  • 19 Feb, 2024
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study of 3 cohorts will be included.

non-small cell lung cancer
EGFR
small cell lung cancer
solid tumour
alopecia
  • 0 views
  • 19 Feb, 2024
Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy

This trial is designed to assess the efficacy of a novel carbon-fibre adjustable reusable accessory (CARA) for breast support to reduce skin toxicity and unwanted normal tissue dose in comparison to the current clinical standard for supine breast support during whole breast RT.

  • 0 views
  • 19 Feb, 2024
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

non-small cell lung cancer
metastatic melanoma
ras-gap
neutrophil count
investigational treatment
  • 0 views
  • 19 Feb, 2024